Implementing Prescriber-Pharmacist Collaborative Care for Evidence-based Anticoagulant Use

Part of paid clinical trials in Ann Arbor, Michigan.

Sponsor
University of Michigan
Study ID
NCT05351749
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • New-prescription Alert — BEHAVIORAL
    An enhanced drug alert notification in the Michigan Medicine electronic health record (EHR) that is tailored to the specific type of inappropriate Direct Oral Anticoagulant (DOAC) use (e.g., dosing too high for renal dysfunction) and offers decision support to the prescriber to alter a newly prescribed DOAC prescription.
  • New-prescription Alert with referral option — BEHAVIORAL
    An enhanced drug alert notification in the EHR that is tailored to the specific type of inappropriate DOAC use (e.g., dosing too high for renal dysfunction) and offers decision support to the prescriber to alter new DOAC prescription. This alert will ALSO include an option for referral to the anticoagulation clinic pharmacist for assistance.
  • Existing-prescription notification to prescriber — BEHAVIORAL
    Prescriber receives a notification through the EHR indicating an existing DOAC prescription may not be appropriate (e.g. due to renal function change, new drug-drug interactions), and recommending a prescription update.
  • Existing-prescription notification to pharmacist — BEHAVIORAL
    Pharmacist receives a notification through the EHR indicating an existing DOAC prescription may not be appropriate (e.g. due to renal function change, new drug-drug interactions), and recommending a prescription update.

Study Details

The researchers hypothesize that existing-prescription notifications directed to pharmacists are more likely to lead to a prescription change than existing-prescription notifications directed to prescribers. Furthermore, the researchers hypothesize that the availability of a pharmacist referral option is associated with a higher rate of prescription changes for initial-prescription alerts that are directed to the prescriber at the time of initial-prescribing errors. Findings from this project will establish a framework for implementing prescriber-pharmacist collaboration for high risk medications, including anticoagulants

Key Dates

Start date
Aug 1, 2022
Status verified
Feb 2026
Primary completion
Dec 15, 2024
Completion
Dec 15, 2024

Study Design

Enrollment
306 participants (actual)
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
HEALTH_SERVICES_RESEARCH

Arms

  • Experimental: New-prescription Alert / Existing-prescription notification to prescriber
  • Experimental: New-prescription Alert w/ referral option/ Existing-prescription notification to prescriber
  • Experimental: New-prescription Alert/ Existing-prescription notification to pharmacist
  • Experimental: New-prescription Alert w/ referral option/ Existing-prescription notification to pharmacist

Primary Outcome Measure

The Number (Proportion) of Notifications (in the Existing-prescription Notification Conditions) That Are Addressed Within 7 Days. [ Time Frame: Up to 7 days ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of MichiganAnn ArborMichigan48109-

Find similar trials in Ann Arbor, MI

By condition
Atrial fibrillation
By specialty
CardiologyHeart disease
By research site
University of Michigan· Ann Arbor, MI

Related Studies